list of her2 article exclusively at San Antonion Breast Cancer Conference

RobinP · 11-09-2008, 07:25 AM

HI ALL, HERE IS THE LIST OF HER2 ARTICLES THAT WILL BE COVERED IN DEC AT THE BIG BC CONFERENCE IN SAN ANTONIO. I LISTED HERE FOR YOU BECAUSE IT TOOK QUITE A WHILE FOR ME TO GO THROUGH AND FIND THIS GROUP OF HER2 ARTICLES.

PS. THE ONE THAT INTEREST AND CONCERNS ME IS HIGHLIGHTED IN RED. THE WORD SIGNIFICANT REALLY IS AN OUCH, OH MY GOD, HELP US ALL HERE, EVEN THE ONES WITH EARLIEST STAGE HER2 BC. NO I AM NOT PLAYING THE DEVIL'S ADVOCATE HERE AND TRYING TO STRESS OR ALARM, BUT I AM VERY CONCERNED. PERHAPS I NEED A PEP TALK? BECKY- YOUR GOOD AT THAT.

Treatment: Her2-Targeted Therapy (Adjuvant and Metastatic) 3131 Molecular marker correlates of clinical outcome in a phase II study of gefitinib or placebo in combination with anastrozole in postmenopausal women with hormone receptor-positive metastatic breast cancer
Valero V, Bacus S, Mangalik A, Rabinowitz I, Arena F, Kroener JF, Curcio E, Watkins C, Magill P, Cristofanilli M. University of Texas MD Anderson Cancer Center, Houston, TX; University of New Mexico, Albuquerque, NM; Arena Oncology Associates, Great Neck, NY; Scripps Health, San Diego, CA; Grupo de Trabajo de Oncologia MÃ©dica, Venezuela, South America; AstraZeneca, Macclesfield, UK. 3132 Randomized phase III study of trastuzumab monotherapy followed by docetaxel and trastuzumab versus the combination of trastuzumab and docetaxel as first-line treatment in patients with HER2 positive metastatic breast cancer
Najagami K, Inoue K, Mizutani M, Hozumi Y, Fujiwara Y, Masuda N, Tsukamoto F, Saito M, Ohashi Y, Sano M, Noguchi S. Shizuoka General Hospital, Shizuoka, Japan; Saitama Cancer Center, Ina-machi, Saitama, Japan; Aichi Cancer Center, Aichi Hospital, Okazaki, Aichi, Japan; Jichi Medical University, Shimotsuke, Tochigi, Japan; National Cancer Center, Chuou-ku, Tokyo, Japan; Osaka National Hospital, Chuou-ku, Osaka, Japan; Osaka Koseinenkin Hospital, Fukushima-ku, Osaka, Japan; Juntendo University, Bunkyo-ku, Tokyo, Japan; Tokyo University, Bunkyo-ku, Tokyo, Japan; Niigata Breast Exam Center, Chuou-ku, NIigata, Japan; Osaka University, Suita, Osaka, Japan. 3133 Final results from a phase II evaluation of lapatinib (L) and bevacizumab (B) in HER2-overexpressing metastatic breast cancer (MBC)
Dickler M, Franco S, Stopeck A, Ma W, Nulsen B, Lyandres J, Melisko M, Lahiri S, Arbushites M, Koehler M, Rugo HS. Memorial Sloan Kettering Cancer Center, New York, NY; Memorial Cancer Institute, Hollywood, FL; Arizona Cancer Center, Tucson, AZ; University of California San Francisco, San Francisco, CA; GlaxoSmithKline, Collegeville, PA. 3134 Circulating regulatory (CD4+CD25+FOXP3+) T cells decrease in breast cancer patients after vaccination with an Ii-Key-modified class II HER2/neu peptide (AE37)
Gates JD, Benavides LC, Carmichael MG, Hueman MT, Holmes JP, Khoo S, Stojadinovic A, von Hofe E, Ponniah S, Peoples GE. Brooke Army Medical Center, Ft. Sam Houston, TX; Dept. of Surgery, USUHS, Bethesda, MD; Naval Medical Center San Diego, San Diego, CA; Walter Reed Army Medical Center, Washington, DC; Antigen Express, Inc., Worcester, MA. 3135 Treatment with trastuzumab in recurrence free patients with early breast cancer and persistent disseminated tumor cells (DTC) in bone marrow
Jueckstock JK, Rack BK, Schindlbeck C, Hofmann S, Zill BJ, Mylonas I, Blankenstein T, Janni WJ, Friese K. Frauenklinik Innenstadt Munich University, Munich, Bavaria, Germany. 3136 A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients with advanced HER2+ breast cancer
Krop IE, Mita M, Burris HA, Birkner M, Girish S, Tibbitts J, Holden SN, Lutzker SG, Modi S. Dana-Farber Cancer Institute, Boston; Institute for Drug Development, San Antonio; Sarah Cannon Research Institute, Nashville; Genentech, Inc., South San Francisco; Memorial Sloan-Kettering Cancer Center, New York. 3137 A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer
Tolaney SM, Najita J, Chen W, Savoie J, Fornier M, Krop IE, Winer EP, Bunnell C. Dana-Farber Cancer Institute, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY. 3138 Efficacy, safety and tolerability of dual monoclonal antibody therapy with pertuzumab + trastuzumab in HER2+ metastatic breast cancer patients previously treated with trastuzumab
Baselga J, Imadalou K, Paton V, Gray D, Swain S. Vall d'Hebron University Hospital, Barcelona, Spain; Roche Products Limited, Welwyn, United Kingdom; Genentech, Inc., South San Francisco; Washington Cancer Institute, Washington Hospital Center, Washington, DC. 3139 Optimal method of dosing HER2/neu peptide vaccines: U.S. Military Cancer Institute Clinical Trials Group Study 1-01, 1-02, 1-03, and 1-04
Benavides LC, Gates JD, Holmes JP, Mittendorf EA, Ponniah S, Peoples GE. Brooke Army Medical Center, Ft. Sam Houston, TX; Naval Medical Center, San Diego, CA; MD Anderson Cancer Center, Houston, TX; Dept. of Surgery, USUHS, Bethesda, MD. 3140 Decrease in serum extracellular domain of HER2 at 4 and 8 weeks is associated with prolonged progression-free survival on lapatinib monotherapy
Lipton A, Leitzel K, Ali S, Carney W, Platek G, O'Rourke L, Martin A-M, Maltzman J. Milton S. Hershey Medical Center, Hershey, PA; Lebanon Veterens Administration, Lebanon, PA; Siemens Healthcare Diagnostics Inc., Cambridge, MA; GlaxoSmithKline, Collegeville, PA. 3141 Association between pathologic complete response and survival in patients treated with sequential anthracyclines and concomitant taxanes and trastuzumab in HER2-positive breast cancer
Mehta RS, Hsiang D, Lane K, Butler J. University of California Irvine School of Medicine, Chao Family Comprehensive Cancer Center, Orange, CA. 3142 Survival of patients with HER2+ metastatic breast cancer and use of trastuzumab following progression: analysis of RegistHER
Rugo H, Kaufman P, Tan-Chiu E, Ulcickas Yood M, Paik S, Yardley D, Brufsky A, Mayer M, Birkner M, Wang L, Brammer M, Tripathy D. UCSF Comprehensive Cancer Center, San Francisco; Dartmouth-Hitchcock Medical Center, Lebanon; Florida Cancer Care, Tamarac; EpiSource, LLC, Yale University School of Medicine, New Haven; National Surgical Breast and Bowel Project, Pittsburgh; Sarah Cannon Research Institute, Nashville; University of Pittsburgh Cancer Center, Pittsburgh; Patient Advocate, New York; Genentech, Inc., South San Francisco; University of Texas Southwestern Medical Center, Dallas. 3143 A novel HER2 inhibitor TAK-285 overcomes trastuzumab resistance of HER2-over-expressing breast cancer
Hayashi A, Tamura T, Yusa T, Takagi S, Ohta Y. Takeda Pharmaceutical Company Limited, Tsukuba, Ibaraki, Japan. 3144 Trastuzumab treatment in elderly patients with advanced breast cancer (ABC) – results from a large observational study
Jackisch C, Hinke A, Schoenegg W, SÃ¶ling U, Stauch M, GÃ¶hler T, KÃ¼hn W, Krieger G, Reichert D. Klinikum, Offenbach, Germany; WiSP, Langenfeld, Germany; Praxen, Berlin, Kassel, Kronach, Dresden, Westerstede, Germany; Charite, Berlin, Germany; Hegau Klinikum, Singen, Germany. 3145 Lapatinib (L) with weekly paclitaxel (P) as first-line therapy for patients (pts) with HER2+ metastatic breast cancer (MBC)
Jagiello-Gruszfeld A, Tjulandin Sergei S, Dobrovolskaya N, Manikhas A, Pienkowski T, Knott A, DeSilvio M, Oliva C. Nzoz Onko-Med, Olsztyn, Poland; Cancer Research Centre, Moscow, Russian Federation; Russian Scientific Center of Roentgeno-Radiology, Moscow, Russian Federation; St Petersburg City Oncological Dispensery, St Petersburg, Russian Federation; Centrum Onkologii - Instytut im Marii Sklodowskiej-Curie, Warsaw, Poland; GlaxoSmithKline Research & Development, London, United Kingdom; GlaxoSmithKline Research & Development, Philadelphia. 3146 Correlation of tumor burden, liver and bone metastasis with serum extracellular domain HER2 expression in front-line metastatic breast cancer
Johnston S, O'Rourke L, Wang W, Pegram M, Press MF, Maltzman J. GlaxoSmithKline, Middlsex, United Kingdom; GlaxoSmithKline, Collegeville, PA; Sylvester Comprehensive Cancer Center, Miami, FL; Los Angeles, CA; Royal Marsden Hospital, London, United Kingdom. 3147 Baseline serum extracellular domain HER2 expression in hormone receptor-positive metastatic breast cancer: correlation with known tissue HER2 status
Johnston S, O'Rouke L, Wang W, Pegram M, Press MF, Maltzman J. GlaxoSmithKline, Collegeville, PA; GlaxoSmithKline, Middlesex, United Kingdom; Sylvester Comprehensive Cancer Center, Miami, FL; USC/Norris Comprehensive Cancer Center, Los Angeles, CA; Royal Marsden Hospital, London, United Kingdom. 3148 Final results of a first line multicenter phase II metastatic breast cancer trial of vinflunine monotherapy and in combination with trastuzumab in HER2+ patients
Yardley DA, McCleod M, Rubin M, Schreiber F, Lange M, Murphy P, Patton J, Thompson DS, Hanson S, Hainsworth JD. SCRI-Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN; Florida Cancer Specialists, Fort Myers, FL; Watson Clinic, Lakeland, FL; Grand Rapids Clinical Oncology Program, Grand Rapids, MI. 3149 Phase II study of liposomal doxorubicin (MyocetÂ®), docetaxel and trastuzumab combination as first line treatment of patients with her-2/neu positive locally advanced or metastatic breast cancer
Amadori D, Gasparini G, Ardizzoni A, Comella G, Saracchini S, Barone C, Bordonaro R, Djazouli K, Barbato A. Istituto Scientifco Romagnolo per lo Studio e Lacura dei Tumori, Meldola, ForlÃ¬-Cesena, Italy; Azienda Complesso Ospedaliero S. Filippo Neri, Roma, Italy; A.O. Universitaria di Parma, Parma, Italy; Fondazione G. Pascale, Napoli, Italy; A.O. Santa Maria Degli Angeli, Pordenone, Italy; Policlinico Universitario A. Gemelli, Roma, Italy; Azienda Garibaldi, Catania, Italy; Cephalon Europe, Paris, France; Cephalon S.r.l., Roma, Italy. 3150 Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes
ChanAS, Freeswick S, Sklarin NT. Memorial Sloan-Kettering Cancer Center, New York, NY. 3151 Multicenter international phase II study of oral vinorelbine (NVBo), capecitabine (X) and trastuzumab (H) triple combination in HER2-positive metastatic breast cancer (MBC): updated results with a longer follow-up
Chan A, Ganju V, Becquart D, Conte P-F, Petruzelka L, Gil-Gil M, Morand M, Vaissiere N, Villanova G, Tubiana-Mathieu N. Mount Hospital, Perth, Australia; Frankston Hospital, Frankston, Australia; AZ Middelheim, Antwerp, Belgium; Policlinico di Modena, Modena, Italy; General Teaching Hospital, Prague, Czech Republic; Institut Catala Oncologia, Hospitalet de Llobregat, Spain; Institut de Recherche Pierre Fabre, Boulogne-Billancourt, France; CHU Dupuytren, Limoges, France. 3152 Treatment of infra-centimetric HER2-positive(+) invasive breast tumors. The Institut Curie experience
Cottu PH, Rodrigues MJ, Kirova Y, Vincent-Salomon A, on Behalf of the Institut Curie Breast Cancer Group. Institut Curie, Paris, France. 3153 Incidence of hormone-receptor negative and basal type breast tumors among HLA-A2+ patients and possible implications for cancer vaccine trials: U.S. Military Cancer Institute clinical trials group study I-01, I-02, I-03, and I-04
Holmes JP, Benavides LC, Gates JD, Mittendorf EA, Ponniah S, Peoples GE. Naval Medical Center San Diego, San Diego, CA; Brooke Army Medical Center, Ft. Sam Houston, TX; UTMD Anderson Cancer Center, Houston, TX; Dept. of Surgery, USUHS, Bethesda, MD. 3154 Circulating tumor cell and endothelial cell data from a phase II evaluation of lapatinib and bevacizumab in HER2-overexpressing metastatic breast cancer
Rugo HS, Dickler M, Franco S, Stopeck A, Lyandres J, Melisko M, Lahiri S, Arbushites M, Koehler M, Lin Y, Scott J, Park J. UCSF, San Francisco, CA; Memorial CI, Hollywood, FL; Arizona CC, Tucson, AZ; GSK, Collegeville, NJ; MSKCC, New York, NY. 3155 HER2 and HER3 cooperatively regulate tumor cell growth and determine sensitivity to the HER kinase inhibitor TAK-285
Takagi S, Hayashi A, Ohta Y. Takeda Pharmaceutical Company Limited, Tsukuba, Ibaraki, Japan. 3156 A multicenter phase II study of non-pegylated liposomal doxorubicin (MYOCETÂ®) in combination with trastuzumab and docetaxel as first line therapy in metastatic breast cancer
Vanturini M, Bighin C, Puglisi F, Contu A, Aitini E, Colucci G, Merlano MC, Paccagnella A, Marini G, CrinÃ² L, Djazouli K, Barbato A. Ospedale Classificato Sacro Cuore Don Calabria, Negrar-Verona, Italy; Isitituto Tumori di Genova, Genova, Italy; Policlinico Universitario, Udine, Italy; Ospedale Civico, Sassari, Italy; Ospedale Carlo Poma, Mantova, Italy; Isituto Oncologico, Bari, Italy; Ospedale Santa Croce e Carle, Cuneo, Italy; Ospedale Civile, Venezia, Italy; Spedali Civili, Brescia, Italy; Azienda Ospedaliera, Perugia, Italy; Cephalon Europe, Paris, France; Cephalon Italy, Rome, Italy. 3157 Lapatinib can restore capecitabine sensitivity in HER2-positive breast cancer
Cha Y, Kim H-P, Han S-W, Oh D-Y, Kim J-H, Im S-A, Bang Y-J, Kim T-Y. Seoul National University Hospital, Seoul, Korea; Seoul National University College of Medicine, Seoul, Korea; Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea. 3158 Cardiac toxicity and adjuvant trastuzumab for breast cancer – the Cancer Centre of Southeastern Ontario experience
Flemming JA, Hopman W, Madarnas Y. Queen's University, Kingston, ON, Canada. 3159 HER2 positive early breast cancers: tumour demographics and trastuzumab therapy in the real-world
Marla S, Roxburgh P, Burton P, Stallard S, Mallon E, Canney P, Cooke T. Glasgow Royal Infirmary, Glasgow, United Kingdom; Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom; Western Infirmary, Glasgow, United Kingdom; Victoria Infirmary, Glasgow, United Kingdom. 3160 Phase II trial of neoadjuvant 5-fluorouracil, epirubicin and cyclophosphamide (FEC100) followed by weekly paclitaxel and trastuzumab (PH) for HER2 positive breast cancer (Kinki Multidisciplinary Breast Oncology Group; KMBOG-0402)
Masuda N, Nakayama T, Matsunami N, Kashiwaba M, Kamigaki S, Yamamura J, Anami S, Takeda M, Yasumura Y, Taguchi T. Osaka National Hospital, Osaka, Japan; Sakai Municipal Hospital, Sakai, Japan; Osaka Rousai Hospital, Sakai, Japan; Iwate Medical University, Morioka, Japan; Yao Municipal Hospital, Yao, Japan; Graduate School of Medicine, Osaka University, Suita, Japan.

Significant increased recurrence rates among breast cancer patients with HER2-positive, T1a,bN0M0 tumors
Rakkhit R, Broglio K, Peintinger F, Cardoso F, Hanrahan EO, Litton JK, Sahin A, Larsimont D, Meric-Bernstam F, Buchholz TA, Valero V, Theriault RL, Piccart M, Ravdin P, Hortobagyi GN, Gonzalez-Angulo AM. MD Anderson Cancer Center, Houston, TX; General Hospital Leoben, Leoben, Austria; Jules Bordet Institute, Brussels, Belgium. 702 Poor survival outcomes in HER2 positive breast cancer patients with low grade, node negative tumours. Implications for trastuzumab therapy?
Tovey SM, Marla S, Brown S, Burton P, Canney P, Stallard S, Mallon E, Edwards J, Cooke T. University Department Surgery GRI, Glasgow, United Kingdom. 703 Influence of anthracycline- and taxane-based neoadjuvant chemotherapy on tumor HER2 protein expression in locally advanced breast cancers: results from the I-SPY TRIAL (CALGB 150007/150012 & ACRIN 6657)
Livasy C, Carey L, DeMichele A, Cowan D, Markey J, Little D, I-SPY Clinical Investigators, Dressler L. Univ of North Carolina, Chapel Hill, NC; Univ of Pennsylvania, Philadelphia, PA; I-SPY Trial Network. 704 Multiplexed AQUA-based assessment of SWOG 9313 shows prognostic value of continuous ER, PR and HER2 assessment
Rimm DL, Barlow WE, Harigopal M, Tedeschi G, Peggy PL, Yeh I-T, Haskell C, Livingston R, Hortobagyi GN, Hayes DF. Yale University School of Medicine, New Haven, CT; HistoRx Inc., New Haven, CT; University of Texas M. D. Anderson Cancer Center, Houston, TX; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; Cancer Research and Biostatistics, Seattle, WA; Fred Hutchinson Cancer Research Center, Seattle, WA; University of Texas Health Science Center at San Antonio, San Antonio, TX; UCLA, Santa Monica, CA; Arizona Cancer Center, Tucson, AZ. 705 A meta-analysis of phase III trials evaluating the predictive value of HER2 and topoisomerase II alpha in early breast cancer patients treated with CMF or anthracycline-based adjuvant therapy
Di Leo A, Isola J, Piette F, Ejlertsen B, Pritchard KI, Bartlett JMS, Desmedt C, Larsimont D, Tanner M, Mouridsen H, O'Malley FP, Twelves C, Cardoso F, Poole CJ, Piccart MJ, Buyse ME. HER2/TOP2A Meta-Analysis Study Group, Prato, Italy; HER2/TOP2A Meta-Analysis Study Group, Finland; HER2/TOP2A Meta-Analysis Study Group, Belgium; HER2/TOP2A Meta-Analysis Study Group, Denmark; HER2/TOP2A Meta-Analysis Study Group, Canada; HER2/TOP2A Meta-Analysis Study Group, United Kingdom. 706 Combination antiHER therapeutics — efficacy of alternative dosing regimens in ER+/HER2+ breast cancer xenografts
Wiechmann LS, Soliz R, Hilsenbeck S, Rimawi M, Osborne CK, Schiff R. Baylor College of Medicine, Houston, TX; Memorial Sloan Kettering Cancer Center, New York, NY. 707 HER2 status and efficay of taxane-based adjuvant therapy of early breast cancer (EBC): a metanalysis of randomized trials involving 7,831 patients
De Laurentiis M, Criscitiello C, Giordano A, Giuliano M, Lauria R, Forestieri V, Montanino A, De Placido S. UniversitÃ* 'Federico II', Napoli, Italy. 708 Lapatinib is active in patients with HER2-amplified breast tumors expressing p95HER2
Guix M, Aura CM, Jimenez J, Scaltriti M, Gomez HL, Doval DC, Ellis C, Gagnon R, Liu Y, Koehler M, Baselga J. Vall d'Hebron University Hospital, Barcelona, Spain; Instituto Nacional de Enfermadades Neoplasicas, Lima, Peru; Rajiv Gandhi Cancer Institute and Research Center, New Delhi, India; GlaxoSmithKline, Collegeville, PA.

Joan M · 11-09-2008, 07:41 AM

Robin,

Thanks for all your work in compiling this information!

Joan

Becky · 11-09-2008, 08:22 AM

Dear Robin

It is difficult to make an assessment on the article - how far out did this study follow these women. Also, it is clear they did not receive Herceptin. Did they receive anything? Most likely they were only followed 1-3 yrs. So... we all know that being Her2+ predicts a worse prognosis but what does that really mean? In general, I think that a Her2+ woman (prior to Herceptin) had a 10% - 25% greater likehood of recurrence than a woman who is Her2 negative BUT highly ER+/PR+. This range depends on how advanced the cancer was when diagnosed. So, therefore, a woman who has a small tumor and negative nodes might have an overall 20% chance of recurrence (prior to Herceptin, prior to an exercise regimen, prior to a healthier lifestyle - all risk of recurrence reducing factors and perhaps prior to having had any chemotherapy but adding in that masectomy or lumpectomy with radiation was employed).

A Her2 neg woman who is highly ER+/PR+ might have a 10% chance of recurrence that is halved to 5% because she would take an AI or tamoxifen. These are the stats doctors are used to because this is the biggest bc population.

The takeaway is that: yes - Her2+ do recur more especially within the first 24 months (Herceptin halves this % and brings us more in line with the common hormone positive/Her2 negative population) but not everyone recurs regardless of stage and Stage 1 women - especially those with tiny tumors, recur less overall. This is true no matter what kind of bc a woman has.

It will be interesting to see the stats on this paper so I guess we will have to wait until December.

BC is scary but always remember that the old adage "worse prognosis" is prior to Herceptin and even without Herceptin, many women never recur with or without chemotherapy.

RobinP · 11-09-2008, 09:10 AM

Becky, thanks for the speedy supportive reply. I knew I could count on you for a calm, rational, and smart response. Sigh, you;re right that we don't have all the information from this article to gather meaningful conclusions at this point. You're also right that aggressive surgical and adjuvant treatments do help decrease rates of relapse, as well as longer NED, beyond the first two years since treatment.

In particular I , too, believe that having had Herceptin improves the prognostic stats. Perhaps this was a study group mentioned in the article didn't have herceptin, or even chemo and adequate surgical clearance. We just don't know and will have to wait until the abstract comes out to see.

You're also right that most her2 relapses happen in the first few years. Unfortunately, no one really knows that long term stat relapse for her2 yet. Let's just hope, the longer out, the better for prognosis. I do know that after five years out, all receptor negative breast cancer relapses less and most her2+ are hormonal negative. That is something positive to keep in mind for those who are her2 and er,pr negative. However, even for those who are her2+ and hormonal positive, it appears that longer out, the less relapse in general.

Yes, Becky, the her2 bc article did upset me. But. I will try to remember what you stated, "that the old adage "worse prognosis" is prior to Herceptin and even without Herceptin, many women never recur with or without chemotherapy. " __________________

Thanks, Becky, and Have a nice day! I love your support; really you are a gem and great bc friend.Thanks for being my am Prozac- ha, ha.